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Abstract
Background: Shifts in pneumococcal serotypes following introduction of 7-valent pneumococcal conjugate vaccine (PCV-7)
may alter the presence of other bacterial pathogens co-inhabiting the same nasopharyngeal niche.
Methodology/Principal Findings: Nasopharyngeal prevalence rates of S. pneumoniae, S. aureus, H. influenzae and M.
catarrhalis were investigated before, 3 and 4.5 years after introduction of PCV-7 in the national immunisation program in
children at 11 and 24 months of age, and parents of 24-month-old children (n<330/group) using conventional culture
methods. Despite a virtual disappearance of PCV-7 serotypes over time, similar overall pneumococcal rates were observed
in all age groups, except for a significant reduction in the 11-month-old group (adjusted Odds Ratio after 4.5 years 0.48,
95% Confidence Interval 0.34–0.67). Before, 3 and 4.5 years after PCV-7 implementation, prevalence rates of S. aureus were
5%, 9% and 14% at 11 months of age (3.59, 1.90–6.79) and 20%, 32% and 34% in parents (1.96, 1.36–2.83), but remained
similar at 24 months of age, respectively. Prevalence rates of H. influenzae were 46%, 65% and 65% at 11 months (2.22, 1.58–
3.13), 52%, 73% and 76% at 24 months of age (2.68, 1.88–3.82) and 23%, 30% and 40% in parents (2.26, 1.58–3.33),
respectively. No consistent changes in M. catarrhalis carriage rates were observed over time.
Conclusions/Significance: In addition to large shifts in pneumococcal serotypes, persistently higher nasopharyngeal
prevalence rates of S. aureus and H. influenzae were observed among young children and their parents after PCV-7
implementation. These findings may have implications for disease incidence and antibiotic treatment in the post-PCV era.
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Introduction
The 7-valent pneumococcal conjugate vaccine (PCV-7; Pre-
venar
TM, Pfizer) prevents nasopharyngeal acquisition of 7
paediatric serotypes in children and transmission to others [1,2].
This results in protection against PCV-7 serotype disease in all age
groups [3–5]. The vacant nasopharyngeal niche in PCV-7
vaccinated children is immediately occupied by non-PCV-7
serotype pneumococci either due to true replacement, unmasking,
or capsular switch, resulting in similar overall pneumococcal
carriage rates [1].
Previous reports have demonstrated potential associations
between pneumococcal presence in the nasopharynx, in particular
vaccine serotypes, and bacteria like H. influenzae, M. catarrhalis or S.
aureus co-inhabiting the same ecological niche [6–8]. This has
raised the concern that shifts in pneumococcal serotypes after
PCV-7 vaccination may facilitate the involvement of other major
contributors to respiratory, as demonstrated in three otitis media
efficacy trials [9–11], or invasive disease in childhood [12–14]. A
temporary increase in S. aureus nasopharyngeal carriage at one
year of age after PCV-7 vaccinations at 2, 4 and 11 months was
previously reported in a randomized controlled trial [15]. Several
years of nationwide PCV-7 vaccine pressure might enhance shifts
in the bacterial ecosystem in infants. Young children are an
important reservoir and major source of transmission of bacteria
to the whole community [14,16,17]. Therefore, the aim of this
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e39730study was to investigate the long-term effects of PCV-7 on
nasopharyngeal carriage of S. pneumoniae, S. aureus, H. influenzae and
M. catarrhalis in healthy PCV-7 vaccinated children and their
unvaccinated parents in the Netherlands.
Methods
Ethics statement
Both cross-sectional studies were approved by an acknowledged
independent ethics committee from the Netherlands (CCMO;
Centrale Commissie Mensgebonden Onderzoek, available at:
http://www.ccmo-omline.nl). Parents of children living in the
western part of the Netherlands were provided with written
information about the study and asked to participate. Written
informed consent was obtained from all parents and the
procedures followed were in accordance with European State-
ments for Good Clinical Practice and the Declaration of Helsinki
of the World Medical Association.
Study design
PCV-7 was implemented in the national immunization program
(NIP) for all infants born after 31 March 2006 at 2, 3, 4 and 11
months of age without a catch-up campaign for older children.
Traditionally, PCV-7 vaccine uptake reached almost 95% [18].
Two subsequent cross-sectional carriage studies of similar design
were conducted to evaluate nasopharyngeal bacterial carriage
after introduction of PCV-7 in the national immunization
program (NIP): 1) 3 years post-PCV-7 (February through July
2009) and 2) 4.5 years post-PCV-7 (September 2010 through
January 2011). In both cross-sectional carriage studies, nasopha-
ryngeal bacterial carriage was evaluated by means of home visits in
two age-cohorts of healthy children vaccinated according to the
Dutch NIP: 1) 11-month-old children after 3 primary doses but
who had not yet, or had within the last week, obtained the booster
dose at 11 months, and 2) 24-month-old children after four doses.
Additionally, nasopharyngeal samples were collected from one of
the parents of each 24-month-old child. Exclusion criteria were
known or suspected immunodeficiency, craniofacial or chromo-
somal abnormalities, coagulation disorders and use of anticoag-
ulant medication. Data of the vaccinated children cohorts and
their parents were compared with data from PCV-7 unvaccinated
children at the age of 12 and 24 months and parents of 24-month-
old children derived from a previous, randomized controlled trial
that had started in the Netherlands well before national PCV7
implementation for infants (NCT00189020) [19]. In this trial,
children had been included at the age of 6 weeks between July
2005 and February 2006 and were followed-up until 24 months of
age.
Procedures
Transnasal nasopharyngeal samples were obtained from chil-
dren and parents by trained study personnel with a nylon flocked
flexible sterile Copan E-swab according to World Health
Organization standard procedures [20]. From parents, an
additional transoral nasopharyngeal sample was collected with a
rigid sterile swab under direct observation of the posterior
pharynx, as the pneumococcal yield is known to be higher in
adults when taking both samples [21]. After sampling, all swabs
were directly inoculated in liquid Amies medium and plated within
24 hours. All the swabs of the three studies were processed by
same laboratory and cultured for presence of S. pneumoniae, S.
aureus, H. influenzae and M. catarrhalis according to standard
bacteriological procedures for conventional culture. One pneu-
mococcal colony per plate was subcultured and serotyped by
Quellung reaction using type-specific antisera from the Statens
Serum Institute (Copenhagen, Denmark). In a post-hoc analysis,
the presence of methicillin resistance was determined in a random
sample of 30 (65%) of the S. aureus strains obtained from children
at 11 months of age 4.5 years after PCV-7 implementation by
using disk diffusion method for cefoxitine and by detection of the
mecA gene [22].
Covariates
Parents of the participating children completed a brief survey on
the following possible predictors of nasopharyngeal bacterial
carriage: age, sex, season of sampling, antibiotic use within one
month prior to sampling, symptoms of a respiratory tract infection
and/or acute otitis media during sampling, presence of siblings in
the household, day care attendance of the participating child,
passive smoke exposure indoors, active smoking of the participat-
ing parent.
Statistical analyses
This study was designed to demonstrate changes in pneumo-
coccal carriage after PCV-7 implementation requiring 330 persons
per group as described previously (4). Assessment of the effects of
PCV-7 on carriage of H. influenzae, M. catarrhalis and S. aureus were
designated secondary outcomes. Given estimated prevalence rates
of 49%, 64% and 5% for H. influenzae, M. catarrhalis and S. aureus in
children based on previous reports [13,20], a sample size of 330
could detect with 80% power and a 2-sided a of 0.05 an increase
of 10%, 9% and 6%, respectively. Differences in prevalence rates
were tested using 2-sided x2 or Fisher’s exact test, where
appropriate. P-values ,0.05 were considered significant. Multi-
variate analysis with backward LR binary logistic regression
modelling was used to obtain adjusted estimates of the association
between the outcomes and intervention as given by adjusted odds
ratio’s (aOR) and their corresponding 95% confidence intervals
(95% CI). All measured possible confounders were entered in this
model and removed when p-value was .0.10. To obtain the aOR
for the intervention effect in case the intervention variable was not
included in the final model (i.e. p-value .0.10), this variable
combined with all remaining variables of the final backward LR
model were entered in a binary logistic regression model without
selection (SPSS version 17.0).
Results
Baseline characteristics of children and their parents before, 3
and 4.5 years after implementation of PCV-7 in the NIP are
shown in Table 1. The most noticeable difference among all three
time-points is the season of sampling.
Carriage of S. pneumoniae
Three years after PCV-7 implementation (post-PCV7), a nearly
complete eradication of PCV-7 serotype carriage in children and
adults was demonstrated, resulting in significant declines in overall
pneumococcal carriage at 11 and 24 months of age and similar
carriage rates in parents [2]. After 4.5 years, PCV-7-serotypes as
well as cross-reactive serotype 6A were found only incidentally in
all age groups (Table S1). Compared to pre-PCV7, overall
pneumococcal prevalence rates had remained significantly lower
at 11 months of age after 4.5 years (adjusted Odds Ratio (aOR)
0.48, 95% Confidence Interval 0.34–0.67), but had risen to similar
levels at 24 months of age and in parents (Table 2). Serotype 19A
became the predominant colonizer in all age groups, followed by
serotypes 6C, 15 B/C and 11A (Table S1).
Changes in Bacterial Carriage Post-PCV-7
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The prevalence of S. aureus was significantly higher in children at
11 months of age (aOR 1.97, 1.04–3.72) and in parents (1.85,
1.36–2.83) 3 years post-PCV7 compared to pre-PCV7. After
4.5 years, a further increase in the prevalence of S. aureus was
observed at 11 months of age (2.26, 1.58–3.33) compared to pre-
PCV7 and results persisted in parents. No changes in S. aureus
carriage were observed in children at 24 months of age after 3 and
4.5 years post-PCV7 (Table 2).No methicillin resistance was
detected in tested isolates (n=30) obtained from 11-month-old
children 4.5 years post-PCV-7.
Carriage of H. influenzae
The prevalence of H. influenzae was significantly higher in
children at 11 months (aOR 2.69, 1.90–3.80), 24 months of age
(2.70, 1.91–3.82) and parents (1.49, 1.03–2.14) after 3 years of
PCV-7 implementation compared to pre-PCV7. After 4.5 years,
higher levels persisted in children, and a further increase in
prevalence of H. influenzae was observed in parents (2.26, 1.58–
3.33) compared to pre-PCV7 (Table 2).
Carriage of M. catarrhalis
The prevalence of M. catarrhalis remained unchanged in
children and parents 3 years post-PCV7 as compared to pre-
PCV7. After 4.5 years, the prevalence of M. catarrhalis remained
similar at 11 months of age, but was significantly higher in children
at 24 months of age (aOR 1.75, 1.18–2.61) and in parents (2.54,
1.59–4.08) compared to pre-PCV7 (Table 2).
Discussion
This is the first study that describes the long-term follow-up of
nasopharyngeal carriage of S. aureus, H. influenzae and M. catarrhalis
next to S. pneumoniae after introduction of PCV-7 in the NIP. In
addition to the virtual elimination of PCV-7 serotypes, we
demonstrated significantly higher S. aureus carriage rates in
children by the end of the first year of life and in the parents
group. For H. influenzae, significantly higher prevalence rates were
detected among children at both 11 and 24 months of age and in
parents. Shifts in nasopharyngeal carriage profiles of these bacteria
may affect disease incidence due to these pathogens in PCV-7
vaccinated children as well as in the population. Moreover,
increased nasopharyngeal carriage may lead to increased exposure
of strains to antibiotics, which may subsequently lead to selection
of resistant ones [23].
The results on S. aureus carriage are consistent with a previous
randomized controlled trial that demonstrated a doubled rate of S.
aureus carriage in healthy children at 12 months of age after 2+1
doses of PCV-7 and in parents as compared to unvaccinated
controls [15]. Similar to our present study, in this trial the impact
of PCV-7 on S. aureus carriage in children was limited to young
children around 12 months of age and no longer present at 18 or
24 months of age. This indicates an effect on S. aureus carriage
when carriage dynamics are at their peak, around PCV-7
vaccinations in infancy, and disappearing later after non-PCV-7
serotypes have filled in the gap or by age-dependent maturation of
the immune system in the second year of life. The impact of
pneumococcal vaccinations on S. aureus presence is also in line with
a randomized controlled trial where an increased rate of S. aureus
culture–positive acute otitis media (AOM) was demonstrated
Table 1. Characteristics of children and their parents before, 3 and 4.5 years after implementation of PCV-7 in the Netherlands.
11 months 24 months
Pre-PCV7 3yr Post 4.5yr Post Pre-PCV7 3yr Post 4.5yr Post
no. (%) no. (%) no. (%) no. (%) no. (%) no. (%)
Children n=319 n=329 n=330 n=321 n=330 n=330
Male sex 156 (49) 181 (55) 173 (52) 155 (48) 187 (57) 171 (52)
Mean age in months (SD) 12.0 (0.3) 10.9 (0.3) 10.7 (0.4) 24.2 (0.6) 24.0 (0.3) 23.8 (0.5)
Presence of siblings ,5yr 126 (40) 84 (26) 145 (44) 127 (40) 135 (41) 154 (47)
Day care attendance
a 208 (65) 226 (69) 222 (67) 224 (70) 233 (71) 259 (79)
Passive smoke exposure
b 21 (7) 5 (2) 9 (3) 26 (8) 16 (5) 12 (4)
Signs of URTI and/or OMA
c 95 (30) 95 (29) 112 (34) 82 (26) 69 (21) 114 (35)
Antimicrobial drug use
d 20 (6) 24 (7) 27 (8) 10 (3) 23 (7) 15 (5)
Period of sampling:
October-March 149 (47) 82 (25) 274 (83) 156 (48) 299 (91) 299 (91)
April-September 170 (53) 247 (75) 56 (17) 166 (52) 31 (9) 31 (9)
Pre-PCV7 3yr Post 4.5yr Post
Parents n=296 n=324 n=326
Male sex 51 (17) 53 (16) 58 (18)
Mean age in years (SD) 34.7 (4.9) 35.1 (4.4) 35.3 (4.5)
Active smoking 40 (14) 34 (11) 41 (13)
Antimicrobial drug use
d 9 (3) 20 (6) 16 (5)
Note. PCV-7; 7-valent pneumococcal conjugate vaccine. SD; standard deviation.
aDefined as more than 4 hours per week with at least 1 child from a different household.
bDefined as passive tobacco smoke exposure indoors at least $1 cigar or cigarette during $5 days/week.
cThe presence of symptoms of an upper respiratory tract
infection (URTI) and/or acute otitis media (OMA) as defined by evaluation of parents.
dDefined as use of oral or intravenous antibiotics within 1 month before sample
was taken.
doi:10.1371/journal.pone.0039730.t001
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recurrent AOM, who were PCV-7-vaccinated followed by the 23-
valent polysaccharide vaccine [11].
In support of these findings, several studies from other sites have
also reported a negative interaction between S. pneumoniae,i n
particular PCV-7-serotypes, and S. aureus carriage in healthy
children [6–8,24] but also during severe pneumonia illness in
HIV-negative children [25]. In contrast to these studies, two
observational studies performed after introduction of PCV-7, one
in children with acute otitis media and one in primary-care visiting
children, did not yield an effect on S. aureus nasopharyngeal
carriage [26,27]. However, these studies included children from
various age groups with different intervals between pneumococcal
vaccinations and the sampling moment, and may not have
detected the temporal impact of PCV-7 on S. aureus carriage
around vaccinations in infancy. Furthermore, no comparison to a
baseline level of S. aureus carriage before PCV-7 implementation
could be made and several methodological concerns were raised
[28].
One possible mechanism of interaction between vaccine
serotype pneumococci and S. aureus is the presence of pneumo-
coccal pilus predicting the absence of S. aureus carriage in
pneumococcal carriers [29]. Host immunological factors may also
play a role, as the negative interaction between S. pneumoniae and S.
aureus is not reported in HIV-positive children [25]. No negative
interaction between S. pneumoniae and S. aureus has been identified
in adults. Although we cannot discriminate the route of intra-
familial transmission in this cross-sectional study, we therefore
hypothesize that vaccinated children induce more transmission of
S. aureus to parents who become colonized for longer periods.
Persistent carriage, as defined by continuous colonisation by the
same strain of S. aureus in time, is a common phenomenon in adults
but rarely detected in infants [8,30].
The observed increase in nasopharyngeal carriage of S. aureus is
worrisome as this is a known risk factor for infection [14,31], and
especially young children in first year of life are vulnerable for S.
aureus disease [32]. In the last decade, only few population-based
studies have been published on invasive S. aureus disease (ISD) after
the introduction of PCV-7. Of those, two large studies from the
USA reported a significant absolute increase in ISD, which could
solely be attributed to an increase in MRSA [33,34] and no other
countries have reported substantial increases so far. Based on our
Table 2. Frequencies of nasopharyngeal carriage and (adjusted) odds ratios of S. pneumoniae, S. aureus, H. influenzae and M.
catarrhalis in children and parents before, 3 and 4.5 years after PCV-7 implementation.
Pre-PCV7 3yr Post
4.5yr
Post 3yr Post vs. Pre-PCV7 4.5yr Post vs. Pre PCV7 4.5yr Post vs. 3yr Post PCV7
no. (%) no. (%) no. (%) OR (95% CI) aOR (95% CI) OR (95% CI) aOR (95% CI) OR (95% CI) aOR (95% CI)
11 months
a: n=319 n=329 n=330
S. pneumoniae 214 (67) 154 (47) 173 (52) 0.43 (0.31–0.59) 0.43 (0.30–0.60) 0.54 (0.39–0.74) 0.48 (0.34–0.67) 1.25 (0.92–1.70) 1.10 (0.79–1.53)
PCV-7-serotypes 122 (38) 25 (8) 10 (3) 0.13 (0.08–0.21) 0.14 (0.09–0.23) 0.05 (0.03–0.10) 0.04 (0.02–0.08) 0.38 (0.18–0.80) 0.32 (0.15–0.69)
Non-PCV-7-
serotypes
92 (29) 129 (39) 166 (50) 1.59 (1.15–2.21) 1.75 (1.24–2.46) 2.50 (1.81–3.46) 2.59 (1.85–3.62) 1.57 (1.15–2.14) 1.47 (1.05–2.05)
S. aureus 16 (5) 31 (9) 46 (14) 1.97 (1.06–3.68) 1.97 (1.04–3.72) 3.07 (1.70–5.54) 3.59 (1.90–6.79) 1.56 (0.96–2.53) 1.88 (1.14–3.13)
H. influenzae 146 (46) 212 (64) 213 (65) 2.15 (1.57–2.94) 2.69 (1.90–3.80) 2.16 (1.57–2.96) 2.22 (1.58–3.13) 1.01 (0.73–1.38) 0.83 (0.59–1.17)
M. catarrhalis 218 (68) 210 (64) 251 (76) 0.82 (0.59–1.13) 0.89 (0.62–1.27) 1.47 (1.04–2.08) 1.25 (0.85–1.83) 1.80 (1.28–2.53) 1.82 (1.27–2.61)
24 months
a: n=321 n=330 n=330
S. pneumoniae 211 (66) 162 (49) 211 (64) 0.50 (0.37–0.69) 0.50 (0.36–0.70) 0.92 (0.67–1.28) 0.81 (0.58–1.13) 1.84 (1.35–2.51) 1.73 (1.26–2.38)
PCV-7-serotypes 114 (36) 14 (4) 11 (3) 0.08 (0.05–0.14) 0.08 (0.05–0.15) 0.06 (0.03–0.12) 0.06 (0.03–0.12) 0.78 (0.35–1.74) 0.76 (0.34–1.70)
Non-PCV-7-
serotypes
97 (30) 148 (45) 200 (61) 1.88 (1.36–2.59) 1.99 (1.43–2.77) 3.55 (2.57–4.92) 3.35 (2.40–4.67) 1.89 (1.39–2.58) 1.78 (1.30–2.44)
S. aureus 18 (6) 25 (8) 24 (7) 1.38 (0.74–2.58) 1.39 (0.74–2.63) 1.32 (0.70–2.48) 1.61 (0.84–3.07) 0.96 (0.54–1.71) 1.09 (0.60–1.97)
H. influenzae 168 (52) 240 (73) 252 (76) 2.43 (1.75–3.37) 2.70 (1.91–3.82) 2.94 (2.10–4.12) 2.68 (1.88–3.82) 1.21 (0.85–1.72) 0.99 (0.68–1.44)
M. catarrhalis 189 (59) 199 (60) 264 (80) 1.06 (0.78–1.45) 1.37 (0.97–1.94) 2.84 (2.00–4.03) 1.75 (1.18–2.61) 2.67 (1.89–3.79) 1.37 (0.85–2.21)
Parents
b: n=296 n=324 n=326
S. pneumoniae 50 (17) 51 (16) 66 (20) 0.92 (0.60–1.41) 0.91 (0.59–1.40) 1.25 (0.83–1.88) 1.22 (0.81–1.84) 1.36 (0.91–2.03) 1.33 (0.89–2.00)
PCV-7-serotypes 25 (8) 2 (1) 7 (2) 0.07 (0.02–0.29) 0.07 (0.02–0.29) 0.24 (0.10–0.56) 0.24 (0.10–0.55) 3.53 (0.73–
17.14)
4.09 (0.83–20.05)
Non-PCV-7-
serotypes
25 (8) 49 (15) 59 (18) 1.93 (1.16–3.22) 1.93 (1.16–3.23) 2.50 (1.52–4.10) 2.43 (1.48–4.00) 1.29 (0.86–1.95) 1.25 (0.82–1.89)
S. aureus 60 (20) 104 (32) 111 (34) 1.86 (1.29–2.68) 1.85 (1.36–2.83) 2.03 (1.41–2.92) 1.96 (1.36–2.83) 1.09 (0.79–1.51) 1.07 (0.77–1.49)
H. influenzae 67 (23) 96 (30) 130 (40) 1.44 (1.00–2.07) 1.49 (1.03–2.14) 2.27 (1.60–3.22) 2.26 (1.58–3.33) 1.58 (1.14–2.18) 1.52 (1.10-2.11)
M. catarrhalis 28 (10) 43 (13) 71 (22) 1.47 (0.88–2.43) 1.44 (0.87–2.39) 2.67 (1.67–4.26) 2.54 (1.59–4.08) 1.82 (1.20–2.76) 1.77 (1.17–2.69)
Note. PCV-7; all serotypes included in 7-valent pneumococcal conjugate vaccine. Non-PCV-7; all other serotypes not included in 7-valent pneumococcal conjugate
vaccine. OR; odds ratio.CI; confidence interval. aOR; adjusted odds ratio. All (a)OR-values are based on comparison with cohort as indicated.
aIn children, OR-values were
adjusted by multivariate analysis for sex, months of sampling, presence of siblings ,5yr in the household, day care attendance, antibiotic use, passive smoke exposure
and the presence of URTI and/or OMA using binary logistic regression with backward LR.
bIn parents, OR-values were adjusted by multivariate analysis for sex, months of
sampling, antibiotic use, active smoking, presence of siblings ,5yr other than participating child and day care attendance of their participating child.
doi:10.1371/journal.pone.0039730.t002
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surveillance, especially after complete eradication of pneumococ-
cal vaccine serotypes and following implementation of broader-
coverage pneumococcal conjugate vaccines in the population,
needs to be implemented.
The long-term impact of PCV-7 implementation on nasopha-
ryngeal carriage of H. influenzae and M. catarrhalis was also
investigated. Two Finnish otitis media trials investigating a
CRM197- or a OMPC-protein based PCV-7 in healthy infants
noted an increase in either H. influenzae or M. catarrhalis in middle-
ear fluid during episodes of AOM, respectively [9,10]. Post-
marketing observational studies in the USA reported relative
increases in both H. influenzae and M. catarrhalis causing AOM in
children after PCV-7 implementation [35,36].
Relatively high nasopharyngeal carriage rates of H. influenzae
and M. catarrhalis were already observed before PCV-7 introduc-
tion in the Netherlands [37]. Nevertheless, we observed significant
increases in H. influenzae carriage in children of both age groups as
well in their parents both 3 and 4.5 years after introduction of
PCV-7. Although no consistent changes in nasopharyngeal
carriage of H. influenzae were observed by conventional culture
techniques in a previous randomized controlled trial evaluating
reduced-dose schedules of PCV-7 [37], a trend towards increased
presence and abundance of Haemophilus species by molecular
techniques was observed in PCV-7 vaccinated children compared
with PCV-7 unvaccinated controls after 2+1 doses of PCV-7
(unpublished data). We therefore hypothesize that implementation
of a full-dose schedule with 4 doses of PCV-7, together with
continuing nationwide PCV-7 vaccine pressure, may have
facilitated increased H. influenzae carriage in our study. In this
study, we have not typed the recovered H. influenzae isolates.
However, between 2008 and 2010, during the same period as the
current study, we conducted a large randomized controlled trial in
the same area in the Netherlands in which 780 infants were
vaccinated with either CRM197-conjugated PCV-7 or Protein-D-
conjugated PCV-10 with carriage of H. influenzae as endpoint.
Similar to the present study, 65% of all cultured swabs were
positive for H. influenzae based on conventional culture methods.
After discrimination from H. haemolyticus by PCR, 92% were
confirmed as H. influenzae. Of these, 8% were encapsulated strains;
most frequently type a (5%) and f (1%) (unpublished data).
As for M. catarrhalis, no consistent changes in carriage after
PCV-7 implementation were found, except for an increase in
carriage in 24-month-old children and their parents 4.5 years post-
PCV7. These results are in line with the randomized controlled
trial which found no changes in M. catarrhalis carriage [37]. Again,
bacterial interference, resource availability and host immunolog-
ical factors may all play a role in the co-existence or competition
between species in the nasopharynx, but the exact mechanisms of
interactions are not yet fully elucidated [38].
With respect to the pneumococcal carriage surveillance study
4.5 years after PCV-7 introduction, we found that PCV-7-serotype
pneumococci and cross-reactive serotype 6A were virtually
eliminated among children and their parents. Simultaneously,
non-PCV-7-serotypes increased significantly and showed higher
diversity. Consistent with reports from other countries, 19A
became the most predominant colonizing serotype in all investi-
gated age groups in the Netherlands, followed by 6C, 15B/C and
11A [39,40]. Also in IPD, serotype 19A has increased significantly
to become the fourth most frequently isolated serotype in the
Netherlands after 7F, 1 and 8. Although frequently carried
serotypes 6C, 15B/C and 11A are now also more frequently found
in IPD, their total number of cases still remained low (unpublished
data). However, due to the adaptive nature of the pneumococcus
[41], long-term nasopharyngeal carriage and IPD surveillance in
all age groups remain essential to evaluate health and economic
impact in the future.
A limitation of the current observational study design is that we
documented associations and no causalities between the introduc-
tion of PCV-7 and changes in nasopharyngeal bacterial carriage
patterns. However, after correction for differences in measured
potential confounders by using multivariate analysis, our results
remained robust. Nonetheless, the impact of other unmeasured
determinants such as the presence of viruses or climatologic factors
cannot be excluded. Also, our results for S. aureus may have been
underestimated due to sampling the nasopharyngeal niche rather
than sampling the anterior nares, which is assumed the ecological
site for S. aureus [14].
Strengths of our study are the consistency of our data measured
in large cohorts at two sequential time points after PCV-7
implementation and compared to a historical baseline. Impor-
tantly, similar standard operating procedures were followed in the
same laboratory for all three studies. Furthermore, we evaluated
the impact of PCV-7 not only in vaccinated infants but also in
unvaccinated adult contacts in a country with PCV-7 uptake of
almost 95% in the NIP [18]. Finally, the studies were performed in
a country with low antibiotic consumption and resistance rates and
therefore unlikely to be confounded by antibiotic resistant clones
[42].
In conclusion, next to large shifts in pneumococcal serotypes, we
observed persistently higher carriage rates of S. aureus and H.
influenzae after PCV-7 implementation in children at a young age
vulnerable for bacterial infections as well as in parents. In addition
to the need for ongoing surveillance of nasopharyngeal bacterial
carriage over time, disease surveillance is warranted to verify
potential clinical consequences of these findings.
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